Fall 2026
AI Researcher Intern
Posted on 5/15/2026
GenScript
1,001-5,000 employees
Global CRO and biologics CDMO services
Compensation Overview
$30/hr
Remote in USA
Remote
Master's, PhD
 AI & Machine Learning (1) |
|---|
Get referred to GenScript
See people who can refer or advise you
- Must be currently pursuing a Master's degree or PhD in an AI related discipline.
- Proficient in Python, familiar with asynchronous programming, concurrency control, and performance optimization
- Familiar with mainstream LLM frameworks (LangChain, LlamaIndex, AutoGen, CrewAI, etc.)
- Experience in large-scale distributed system design and implementation
- Familiar with containerization technologies such as Docker and Kubernetes
- Deep understanding of Transformer architecture and large model principles
- Familiar with Prompt Engineering, Function Calling, Tool Use, and related technologies
- Experience in RAG system development, familiar with vector retrieval, text Embedding, re-ranking, and related techniques
- Understanding of reinforcement learning fundamentals; experience with RLHF, DPO, and related methods is a plus
- Ability to conduct independent technical research, responsible for the entire process from problem definition to solution implementation
- Strong literature reading and summarization skills, able to quickly absorb cutting-edge research achievements
- Capability in technology selection and evaluation, able to make reasonable decisions among multiple solutions
- Strong passion for AI technology, keeping up with the latest developments in the Agentic AI field
- Excellent communication and collaboration skills, able to work efficiently with engineering teams
- Critical thinking ability, capable of objectively evaluating and iteratively optimizing technical solutions
- Research and design Agent execution framework, providing standardized runtime environment for intelligent agents
- Implement tool call orchestration mechanism, supporting unified abstraction for function calling, API integration, and external system interaction
- Build execution sandbox environment to ensure safety and controllability of Agent operations
- Design task decomposition and planning engine, supporting automatic breakdown of complex goals and execution path optimization
- Implement execution state tracking and anomaly recovery mechanisms to ensure reliability of long-running tasks
- Design hierarchical memory architecture, covering storage and retrieval mechanisms for working memory, short-term memory, and long-term memory
- Research memory compression and summarization techniques, enabling efficient storage of massive interaction history while preserving key information
- Build context-aware memory system, supporting multi-dimensional memory association based on time, task, and user
- Develop memory retrieval augmentation mechanisms, achieving deep integration of RAG and Agent memory
- Explore memory forgetting and update strategies, balancing memory capacity with information timeliness
- Research multi-Agent system architecture, design communication protocols and collaboration mechanisms between Agents
- Implement role specialization and task allocation algorithms, supporting orchestration of expert Agents, coordinator Agents, executor Agents, and other roles
- Build consensus achievement and conflict resolution mechanisms to handle decision disagreements among multiple Agents
- Design Agent social behavior norms, simulating communication, negotiation, and feedback patterns in human team collaboration
- Explore emergent behavior and collective intelligence, researching self-organization and adaptive capabilities in multi-Agent systems
- Design Agent evaluation and benchmarking system, establishing quantitative capability metrics
- Build Agent behavior interpretability framework, supporting decision process tracing and attribution analysis
- Research Agent safety alignment mechanisms to prevent risks such as unauthorized operations, harmful outputs, and goal drift
- Track cutting-edge Agentic AI research and translate academic achievements into engineering practice
GenScript Biotech Corporation is a global CRO and biologics CDMO. It provides services and products for life sciences, including custom gene synthesis, peptide synthesis, protein expression/purification, antibody development, and CRISPR, and it supports cell and gene therapy through its ProBio CDMO, Bestzyme enzymes, and Legend Biotech platforms. The company differentiates itself by operating across four platforms that cover research services, end-to-end therapy development, industrial enzymes, and integrated cell therapy, with a global customer base and notable collaborations such as Legend Biotech’s CAR-T program with Janssen. Its goal is to help customers accelerate drug discovery and biopharmaceutical development, scale manufacturing, and bring cell- and gene-therapy products to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Piscataway Township, New Jersey
Founded
2002
Get referred to GenScript
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 revenue rose 27.3% to US$404.2 million, with profit up 203.3%.
- GenScript and Tamarind Bio's August 2026 partnership expands AI-to-lab validation demand.
- ProBio revenue jumped 34.2% in H1 2026, and new orders rose 54%.
What critics are saying
- US lawmakers renewed GenScript national-security scrutiny in 2025, inviting future restrictions.
- ProBio's September 2026 spin-off depends on approvals, market conditions, and execution.
- H1 2026 still showed a US$129.3 million net loss from Legend equity accounting.
What makes GenScript unique
- GenScript's Gene-to-Protein platform compresses AI design into four-day wet-lab validation.
- ProBio connects discovery, development, and GMP manufacturing across biologics and advanced therapies.
- Legend Biotech's CARVYKTI legacy gives GenScript credibility with top-tier oncology partners.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Short Term Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Company Holidays
Paid Sick Days
Compassionate Leave
Jury Duty Leave
Float day
Personal days
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↓ -2%Genscript shares slump 12pc on proposed spinoff of Probio Technology. 4 hours ago GenScript Biotech Corporation. GenScript Biotech Corporation (1548) saw its shares plunge nearly 12 percent in early trading on Friday after announcing a proposed spin-off and separate listing of its subsidiary Probio Technology on the main borad. The arm operates Genscript's biologics and advanced therapy contract research, development, and manufacturing organization services, according to an exchange filing. The company said it submitted an application to the Stock Exchange on August 14, while details of the proposed spin-off have yet to be finalized After the proposed spin-off is completed, the biotech firm noted that it will continue to hold a controlling interest in ProBio, which will remain a subsidiary of the company, and its financial results will continue to be consolidated into the group's financial statements.
GenScript reports 27.3% First-Half 2026 revenue growth as AI Drug Discovery business doubles. GenScript Biotech Corporation 2026-08-18 22:15 332 Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ - GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services. GenScript Biotech Corporation reports 27.3% revenue growth in the first half of 2026. The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine. GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability. "Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery." First-Half 2026 Highlights GenScript Life Science Group * Revenue of approximately US$319.0 million, up 28.8% * Adjusted gross profit of approximately US$184.5 million, up 46.1% * Adjusted operating profit of approximately US$94.0 million, up 102.8% * Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine AI-Enabled Drug Discovery * AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period * Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem * Revenue increased 34.2% on a comparable basis to approximately US$61.1 million * New orders increased 54% * Adjusted operating loss narrowed 22.5% to US$24.3 million * Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027 * Revenue of approximately US$30.4 million, up 7.4% * Adjusted gross profit of approximately US$13.0 million, up 14.0% Integrated Capabilities Support Growth Across the Portfolio The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow. GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers. To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex. Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development. GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses. The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation. Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website. About GenScript Biotech Corporation Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com. Investor and Media Contacts
GenScript reports 27.3% First-Half 2026 revenue growth as AI Drug Discovery business doubles. August 18, 2026 Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ - GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services. GenScript Biotech Corporation reports 27.3% revenue growth in the first half of 2026. The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine. GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability. "Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery." First-Half 2026 Highlights GenScript Life Science Group * Revenue of approximately US$319.0 million, up 28.8% * Adjusted gross profit of approximately US$184.5 million, up 46.1% * Adjusted operating profit of approximately US$94.0 million, up 102.8% * Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine AI-Enabled Drug Discovery * AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period * Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem * Revenue increased 34.2% on a comparable basis to approximately US$61.1 million * New orders increased 54% * Adjusted operating loss narrowed 22.5% to US$24.3 million * Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027 * Revenue of approximately US$30.4 million, up 7.4% * Adjusted gross profit of approximately US$13.0 million, up 14.0% Integrated Capabilities Support Growth Across the Portfolio The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow. GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers. To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex. Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development. GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses. The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation. Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website. About GenScript Biotech Corporation Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com. Investor and Media Contacts
GenScript Biotech reported first-half 2026 revenue of approximately $404.2 million, up 27.3% year over year, while adjusted net profit surged 203.3% to roughly $62.5 million. The company's AI-enabled drug discovery business doubled compared to the previous year, marking its third consecutive half-year of rapid growth. Gene-to-Protein accounted for about 66% of GenScript Life Science Group revenue and remained the primary growth driver. The platform combines scientific expertise, automation, and global manufacturing capacity to support drug discovery and development. GenScript Life Science Group generated revenue of approximately $319 million. ProBio revenue reached roughly $61.1 million, with the unit expecting positive adjusted EBITDA by 2027. Bestzyme reported revenue of about $30.4 million. The company attributes growth to increased demand from AI-focused biotechnology companies and pharmaceutical innovators requiring experimental validation and development services.
Genscript biotech reports higher underlying profit amid segment growth. August 16, 2026 at 10:39 AM UTC - By FilingReader AI Genscript Biotech reported group revenue of US$404,216k for the six months ended 30 June 2026, representing a 27.3% year-over-year increase on an underlying basis. Gross profit reached US$206,711k, up 48.0% underlying, while adjusted net profit climbed 203.3% to US$62,523k. However, taking into account equity accounting impacts from Legend Group, the company recorded a net loss after income tax of US$129,344k for the period. Performance across business segments showed positive momentum, led by the GenScript Life Science Group with external revenue of US$315,218k. ProBio and Bestzyme contributed external revenues of US$58,028k and US$30,387k respectively, with ProBio narrowing its adjusted operating loss and Bestzyme seeing a 7.4% revenue increase. This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact [email protected]